Incidentaloma differential diagnosis: Difference between revisions
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Adrenal gland|Adrenal]] incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal [[adenoma]], [[adrenocortical carcinoma]], [[Cushing's syndrome]], [[pheochromocytoma]], and [[metastasis]]. | [[Adrenal gland|Adrenal]] incidentaloma must be differentiated from other diseases that cause [[Adrenal gland|adrenal]] masses such as [[Adrenal gland|adrenal]] [[adenoma]], [[adrenocortical carcinoma]], [[Cushing's syndrome]], [[pheochromocytoma]], and [[metastasis]]. | ||
==Differentiating different causese of Incidentaloma== | ==Differentiating different causese of Incidentaloma== | ||
Line 18: | Line 18: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
**Symptoms related to | **Symptoms related to excess [[glucocorticoid]] | ||
**Symptoms related to | **Symptoms related to excess [[mineralocorticoid]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Line 32: | Line 32: | ||
* [[Cortisol level]] | * [[Cortisol level]] | ||
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | * Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | ||
* [[Renin]] (PRA) or plasma renin concentration (PRC): | * [[Renin]] (PRA) or plasma [[renin]] concentration (PRC): Very low in patients with [[Hyperaldosteronism|primary aldosteronism,]] usually less than 1 ng/mL per hour for PRA and usually undetectable for PRC<ref /> | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]] | ||
Line 44: | Line 44: | ||
*Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]] | *Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]] | ||
*[[Tumor]] [[calcification]] | *[[Tumor]] [[calcification]] | ||
*Diameter usually >4 cm | *Diameter usually > 4 cm | ||
*Unilateral location | *Unilateral location | ||
*High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) | *High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) | ||
Line 53: | Line 53: | ||
*Evidence of local invasion or [[Metastasis|metastases]] | *Evidence of local invasion or [[Metastasis|metastases]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Androgen|Adrenal androgens]] [[ | * [[Androgen|Adrenal androgens]] ([[Dehydroepiandrosterone|DHEAS]]) | ||
* [[Androstenedione]] | * [[Androstenedione]] | ||
* Bioavailable [[testosterone]] should be measured in every patient. | * Bioavailable [[testosterone]] should be measured in every patient. | ||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | * [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | ||
* Serum [[estradiol]] in men and | * Serum [[estradiol]] in men and post-menopausal women | ||
* [[Cortisol level]] | * [[Cortisol level]] | ||
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | * Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | ||
Line 72: | Line 72: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* 24-hour urine [[cortisol]] | * 24-hour urine [[cortisol]] | ||
* | * Mid-night salivary [[cortisol]] | ||
* Low dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]]. | * Low dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]]. | ||
|- | |- | ||
Line 83: | Line 83: | ||
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]]. | * Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]]. | ||
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients. | * It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients. | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Increased attenuation on nonenhanced [[Computed tomography|CT]] (>20 HU) | * Increased attenuation on nonenhanced [[Computed tomography|CT]] ( > 20 HU) | ||
* Increased [[mass]] vascularity | * Increased [[mass]] vascularity | ||
* Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | * Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | ||
Line 104: | Line 104: | ||
**Irregular shape and inhomogeneous nature | **Irregular shape and inhomogeneous nature | ||
**Tendency to be bilateral | **Tendency to be bilateral | ||
**High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]] | **High unenhanced [[Computed tomography|CT]] attenuation values ( > 20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]] | ||
**Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | **Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | ||
** | **Iso-intensity or slightly less intense than the liver on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content) | ||
**Elevated standardized uptake value on FDG-[[PET scan]] | **Elevated standardized uptake value on FDG-[[PET scan]] | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| | | | ||
|} | |} | ||
Line 260: | Line 260: | ||
* Urine [[toxicology]] [[Screening (medicine)|screening]] | * Urine [[toxicology]] [[Screening (medicine)|screening]] | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" | Labile hypertension ([[White coat hypertension]]) | | style="background:#DCDCDC;" align="center" | Labile hypertension ([[White coat hypertension]]) | ||
| | | | ||
* No history of [[hypertension]] | * No history of [[hypertension]] | ||
Line 302: | Line 302: | ||
* [[Ultrasonography]] (might not be very accurate in [[obese]] patients or those with [[intestinal]] gas)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup> | * [[Ultrasonography]] (might not be very accurate in [[obese]] patients or those with [[intestinal]] gas)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup> | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" | [[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]]) | | style="background:#DCDCDC;" align="center" | [[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]]) | ||
| | | | ||
* Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and neurogenic [[paroxysmal hypertension]]. | * Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and neurogenic [[paroxysmal hypertension]]. | ||
Line 348: | Line 348: | ||
* A neuroimaging study should be performed in all adults with a first seizure to evaluate structural brain abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]]. | * A neuroimaging study should be performed in all adults with a first seizure to evaluate structural brain abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]]. | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" |[[Carcinoid syndrome]] | | style="background:#DCDCDC;" align="center" |[[Carcinoid syndrome]] | ||
|[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229 }}</ref>. Symptoms include: | |[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229 }}</ref>. Symptoms include: | ||
* Severe [[chest]] pain | * Severe [[chest]] pain | ||
Line 371: | Line 371: | ||
* [[Computed tomography|CT]] is recommended for evaluation of all patients with [[Carcinoid syndrome|carcinoid tumors]].<ref name="pmid19077417">{{cite journal| author=Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society| title=ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. | journal=Neuroendocrinology | year= 2009 | volume= 90 | issue= 2 | pages= 167-83 | pmid=19077417 | doi=10.1159/000184855 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19077417 }}</ref> | * [[Computed tomography|CT]] is recommended for evaluation of all patients with [[Carcinoid syndrome|carcinoid tumors]].<ref name="pmid19077417">{{cite journal| author=Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society| title=ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. | journal=Neuroendocrinology | year= 2009 | volume= 90 | issue= 2 | pages= 167-83 | pmid=19077417 | doi=10.1159/000184855 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19077417 }}</ref> | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" |[[Migraine headaches]] | | style="background:#DCDCDC;" align="center" |[[Migraine headaches]] | ||
| | | | ||
* '''Prodrome:''' | * '''Prodrome:''' | ||
Line 408: | Line 408: | ||
* Differentiating a migraine from other primary [[headaches]] | * Differentiating a migraine from other primary [[headaches]] | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" |Drugs | | style="background:#DCDCDC;" align="center" |Drugs | ||
|[[Sympathomimetic drug|Sympathomimetic drugs]] that can induce symptoms simulating pheochromocytoma include: | |[[Sympathomimetic drug|Sympathomimetic drugs]] that can induce symptoms simulating pheochromocytoma include: | ||
* High-dose [[phenylpropanolamine]] | * High-dose [[phenylpropanolamine]] | ||
Line 424: | Line 424: | ||
* [[Urine]] [[Toxicology screen|toxicology screening]] | * [[Urine]] [[Toxicology screen|toxicology screening]] | ||
|- | |- | ||
|style="background:#DCDCDC;" align="center" | [[Baroreflex|Baroreflex failure]]<ref name="pmid8413455">{{cite journal| author=Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM| title=The diagnosis and treatment of baroreflex failure. | journal=N Engl J Med | year= 1993 | volume= 329 | issue= 20 | pages= 1449-55 | pmid=8413455 | doi=10.1056/NEJM199311113292003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8413455 }}</ref> | | style="background:#DCDCDC;" align="center" | [[Baroreflex|Baroreflex failure]]<ref name="pmid8413455">{{cite journal| author=Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM| title=The diagnosis and treatment of baroreflex failure. | journal=N Engl J Med | year= 1993 | volume= 329 | issue= 20 | pages= 1449-55 | pmid=8413455 | doi=10.1056/NEJM199311113292003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8413455 }}</ref> | ||
| | | | ||
* Marked and frequent fluctuations in [[blood pressure]],<ref name="pmid183225442">{{cite journal| author=Zar T, Peixoto AJ| title=Paroxysmal hypertension due to baroreflex failure. | journal=Kidney Int | year= 2008 | volume= 74 | issue= 1 | pages= 126-31 | pmid=18322544 | doi=10.1038/ki.2008.30 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18322544 }}</ref> with both high and low readings. | * Marked and frequent fluctuations in [[blood pressure]],<ref name="pmid183225442">{{cite journal| author=Zar T, Peixoto AJ| title=Paroxysmal hypertension due to baroreflex failure. | journal=Kidney Int | year= 2008 | volume= 74 | issue= 1 | pages= 126-31 | pmid=18322544 | doi=10.1038/ki.2008.30 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18322544 }}</ref> with both high and low readings. |
Revision as of 15:31, 7 November 2017
Incidentaloma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Incidentaloma differential diagnosis On the Web |
American Roentgen Ray Society Images of Incidentaloma differential diagnosis |
Risk calculators and risk factors for Incidentaloma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Adrenal incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal adenoma, adrenocortical carcinoma, Cushing's syndrome, pheochromocytoma, and metastasis.
Differentiating different causese of Incidentaloma
- The cause of adrenal incidentaloma commonly include adrenal adenoma, sub-clinical Cushing's syndrome, pheochromocytoma, and adrenocortical carcinoma. These causes can be differentiated from each other as follows:
Differential Diagnosis | Clinical picture | Imagings | Laboratory tests | |
---|---|---|---|---|
Adrenal adenoma |
|
|
| |
Adrenocortical carcinoma |
|
|
| |
Cushing's syndrome |
|
|
| |
Pheochromocytoma |
|
|
| |
Adrenal metastasis |
|
|
Differential diagnosis of Cushing's disease from other diseases
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertension, hyperandrogenism, and obesity. Facial plethora, skin changes, osteoporosis, nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[1][2][3][4]
Differentiating pheochromocytoma from other diseasesPheochromocytoma must be differentiated from other causes of paroxysmal hypertension. The differentials include:
References
|